

[New Drug Approvals](#)

Generic Name (Trade Name) Company

October 30, 2018

Estradiol and progesterone capsules

(Bijuva—TherapeuticsMD)

Bioidentical hormone therapy reduces hot flashes due to menopause

Uses/Notes

FDA approved [Bijuva](#) (TherapeuticsMD), the first bioidentical oral hormone combination of estradiol and progesterone (1-mg/100-mg capsule) to treat moderate to severe hot flashes in women with a uterus.

Approval was based on the Phase III Replenish Trial, in which Bijuva demonstrated a statistically significant reduction from baseline in both the frequency and severity of hot flashes compared with placebo, while reducing the risks to the endometrium.

The most common adverse reactions (~3%) were breast tenderness, headache, vaginal bleeding, vaginal discharge, and pelvic pain. No clinically significant changes were found in lipid, coagulation, or glucose parameters compared with placebo, and no unexpected safety signals were noted.

The recommended dosage is one tablet orally each evening with food.

Bijuva comes with a boxed warning; see the [prescribing information](#) for more information.

The drug will be available in the United States in the second quarter of 2019.

Source URL:

<http://aphanet.org/new-drug-approvals/bioidentical-hormone-therapy-reduces-hot-flashes-due-menopause>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.